Compare MESO & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MESO | CHCO |
|---|---|---|
| Founded | 2004 | 1957 |
| Country | Australia | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 1995 |
| Metric | MESO | CHCO |
|---|---|---|
| Price | $13.93 | $130.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $132.50 |
| AVG Volume (30 Days) | ★ 136.6K | 72.3K |
| Earning Date | 02-26-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | N/A | ★ 13.18 |
| EPS | N/A | ★ 2.20 |
| Revenue | N/A | N/A |
| Revenue This Year | $629.74 | $5.16 |
| Revenue Next Year | $30.65 | $3.12 |
| P/E Ratio | ★ N/A | $58.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $113.21 |
| 52 Week High | $21.50 | $133.59 |
| Indicator | MESO | CHCO |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 68.17 |
| Support Level | $13.71 | $120.54 |
| Resistance Level | $16.14 | $131.33 |
| Average True Range (ATR) | 0.47 | 2.31 |
| MACD | -0.07 | 0.61 |
| Stochastic Oscillator | 11.08 | 95.12 |
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.